Search

Research on tuberous sclerosis, a rare genetic disorder affecting the TSC1 and TSC2 genes, was discussed by a researcher at Jawaharlal Nehru Medical College in Maharashtra, India. The study highlighted the challenges in managing neuropsychiatric manifestations in individuals with tuberous sclerosis, emphasizing the need for early recognition and prompt treatment. The lack of appropriate guidelines for managing these manifestations poses a significant challenge, indicating the necessity for further research in this area. [Extracted from the article]

Researchers from the University of Pompeu Fabra in Barcelona, Spain, have developed a new thermodynamics-inspired Temporal Evolution NETwork (TENET) framework to study the asymmetry in the flow of events, or the 'arrow of time', in human brain signals. This framework was applied to neuroimaging data from the Human Connectome Project and revealed significant differences in brain dynamics between resting states and various cognitive tasks. The study suggests that the default mode network (DMN) plays a crucial role in orchestrating brain hierarchy and that this hierarchy differs between healthy individuals and those with neuropsychiatric disorders. The research provides valuable insights into the fundamental principles of brain dynamics in complex cognitive environments. [Extracted from the article]

Researchers have conducted studies on targeting orexin receptors for the treatment of neuropsychiatric disorders. Orexin-A and orexin-B are neuropeptides that act through two distinct receptors, OX1-R and OX2-R, with various physiological functions. The research focuses on the development of subtype-selective or dual ligands for these receptors, discussing their potential applications in neuropsychiatric diseases. This peer-reviewed research provides insights into the molecular basis of receptor recognition and the design of ligands for therapeutic purposes. [Extracted from the article]

The article discusses a study that created a single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex, focusing on neurodegenerative and neuropsychiatric diseases. The study included specimens from 1,494 unique donors affected by various brain disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, and bipolar disorder. The research revealed shared and distinct molecular mechanisms across these diseases, highlighting potential targets for therapeutic intervention. This preprint has not yet undergone peer review. [Extracted from the article]

The article discusses the complexities of rare heterozygous neurexin-1 deletions and their impact on neuropsychiatric disorders. It highlights the importance of tailored therapeutic strategies due to the diverse mutations affecting the same gene. The study explores how these deletions affect synaptic activity in different types of brain cells, emphasizing the need for precision medicine to address individual variations in gene mutations. The research suggests that understanding whether mutations act through loss-of-function or gain-of-function mechanisms is crucial for personalized treatment approaches in neuropsychiatric disorders. [Extracted from the article]

Researchers from the University of Texas Health Science Center in Houston conducted a study on the impact of maternal dysbiosis on offspring behavior. The research found that advanced maternal age can lead to neurodevelopmental and neuropsychiatric disorders in offspring. By recolonizing young female mice with aged female microbiome prior to pregnancy, the study showed that offspring displayed persistent depressive- and anxiety-like phenotypes. The findings suggest that age-related changes in the maternal gut microbiome can contribute to long-lasting behavioral changes in offspring, highlighting the potential of microbiome-targeted approaches to reduce the risk of neuropsychiatric disorders. [Extracted from the article]

Leal Therapeutics, a biotechnology company focusing on central nervous system disorders, secured a $45 million financing round led by Newpath Partners, Chugai Venture Fund, and Alexandria Venture Investments. The funding will support the development of antisense oligonucleotide and small molecule therapeutics for conditions like amyotrophic lateral sclerosis and schizophrenia. Leal plans to submit Investigational New Drug applications for their lead programs by the end of 2024 and begin clinical trials in early 2025, aiming to address unmet medical needs in neurodegenerative and neuropsychiatric disorders. [Extracted from the article]

The article explores the genetic correlations and causal associations between atopic dermatitis (AD) and neuropsychiatric disorders such as attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BP), major depressive disorder (MDD), and schizophrenia (SCZ). Through genome-wide association data, the study identified significant positive genetic correlations between AD and ADHD, MDD, and BP, highlighting shared molecular mechanisms and inflammatory pathways as key contributors to both disease categories. The research suggests potential implications for therapeutic interventions targeting common inflammatory mechanisms but has not yet undergone peer review. [Extracted from the article]

Researchers at the Polish Academy of Sciences have reported new data on the potential use of psilocybin in treating mental disorders. Studies suggest that psilocybin may act as a fast-acting antidepressant by affecting glutamate levels in the brain. The research aims to explore the impact of psilocybin on glutamatergic neurotransmission and its therapeutic effects in neuropsychiatric diseases. This study has been peer-reviewed and offers valuable insights into the potential mechanisms of action of psilocybin in mental health treatment. [Extracted from the article]

A recent study from West China Second University Hospital explores the effects of prenatal hyperandrogenism on offspring health, revealing significant impacts on cardiovascular, metabolic, reproductive, and neuropsychiatric health. Elevated prenatal androgen levels disrupt fetal development, leading to long-term consequences such as cardiovascular dysfunction, metabolic abnormalities, reproductive system issues like polycystic ovary syndrome, and increased risks of neuropsychiatric disorders like autism spectrum disorder and anxiety. The research highlights the need for further study to develop interventions to mitigate these adverse effects. [Extracted from the article]

A recent study conducted at University Hospital in Parma, Italy, focused on pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, specifically Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). The study aimed to evaluate consensus on the definition, diagnostic criteria, treatment, and follow-up of PANS and PANDAS in pediatric patients. The researchers highlighted the need for more randomized controlled trials to improve the management and outcomes of these conditions in children. For more information, readers can access the full article in Frontiers in Immunology. [Extracted from the article]

The article discusses the molecular specification of certain neurons in the brain and their connectivity, particularly focusing on the ventropallial excitatory neurons in the claustro-amygdalar complex and piriform cortex. It highlights the role of transcription factors SOX4, SOX11, and TFAP2D in the development and connectivity of these neurons, emphasizing their importance in cognitive and sensory information processing. The study suggests that disruptions in these circuits during early life may be linked to neuropsychiatric disorders, shedding light on potential mechanisms underlying such conditions. [Extracted from the article]

Researchers from Wuhan University in Hubei, China, have developed a new model for classifying neuropsychiatric disorders using multi-modal data. The model combines a multi-scale image features extraction neural network with XGBoost to achieve high accuracy in classification. The study aims to provide psychiatrists with ideas for comparative examinations and diagnosis, enhancing interpretability and understanding of mental disorders. This research has been peer-reviewed and offers valuable insights into the field of neuropsychiatry. [Extracted from the article]

Researchers from the University of California Los Angeles (UCLA) conducted a study on carriers of reciprocal 22q11.2 copy number variants to explore the relationship between inflammation and neuropsychiatric symptoms. The study found that 22qDup carriers had elevated levels of IL-8 compared to control participants, and 22qDelPS+ carriers exhibited increased levels of IL-8 relative to those without psychosis risk symptoms. The research suggests that CNVs at the 22q11.2 locus may impact inflammatory processes related to IL-8, potentially influencing psychosis risk symptoms. Further research is needed to understand the mechanisms behind these findings. [Extracted from the article]

Dr. Margaret M. McCarthy, PhD, a neuroscientist at the University of Maryland School of Medicine, has been elected as a member of the National Academy of Medicine for her groundbreaking research on sex differences in developing brains. Her work focuses on the impact of hormones, inflammation, and immune system on neuroanatomical and behavioral outcomes, shedding light on neuropsychiatric disorders. Dr. McCarthy's research has led to new policies mandating the consideration of sex and gender in preclinical research and drug dosing, aiming to improve treatment outcomes for both men and women. [Extracted from the article]

Researchers from the First Bethune Hospital of Jilin University in China have conducted a study on the Quaking protein (QKI) and its role in neuropsychiatric disorders and tumor progression. The study highlights QKI's involvement in the development of the nervous system, cardiovascular system, and its association with neuropsychiatric disorders such as schizophrenia, depression, ataxia, and Alzheimer's disease. The research emphasizes the need for further basic and clinical trials to understand the mechanisms of QKI in these conditions. For more information, readers can refer to the article "The multifaceted role of quaking protein in neuropsychiatric disorders and tumor progression" published in Frontiers in Neuroscience. [Extracted from the article]

Researchers from Beijing Jiaotong University in China have developed a novel deep learning model called RS-MAE for classifying neuropsychiatric disorders based on resting-state fMRI data. The RS-MAE model addresses issues of information redundancy and sample insufficiency in traditional deep models, achieving high accuracies in classifying disorders such as ADHD, ASD, AD, and SCZ. This research, published in IEEE Transactions on Neural Networks and Learning Systems, demonstrates the effectiveness of RS-MAE in improving classification performance for neuropsychiatric disorders. [Extracted from the article]

Nevro Corp. has been issued a patent for electrical therapy applied to the brain with increased efficacy and decreased side effects. The therapy signal has a higher frequency range of 5 kHz to 100 kHz, aiming to reduce or eliminate motor, sensory, and neuropsychiatric disorders without inducing unwanted side effects like paresthesia or cognitive impairment. This technology offers potential improvements in treating conditions such as Parkinson's disease and speech disorders, with the goal of producing more effective outcomes with fewer complications. [Extracted from the article]

Researchers from the University of California have detailed the role of interferon signaling in neurodegeneration and neuropsychiatric disorders. Recent studies have shown heightened interferon responses in neurodegenerative diseases such as Alzheimer's, Parkinson's, and related mouse models. The research highlights the involvement of IFN-responsive T cells in the brain and peripheral blood, as well as the implications of dysregulated IFN signaling in neuropsychiatric disorders like major depression and PTSD. The study aims to integrate advances in understanding IFN responses in these conditions, considering factors like sex and ancestry, and exploring potential mechanistic explanations for the upregulation of antiviral-like IFN signaling pathways in non-viral neurological and psychiatric disorders. [Extracted from the article]

A recent study from Yale University explores the role of class III HDACs (Sirtuins) in neuropsychiatric diseases, focusing on their unique functional activity and significance in normal neurophysiology, addiction, mood disorders, and other neuropsychiatric abnormalities. The research highlights the importance of understanding the differences in catalytic structure and function of the seven sirtuins in relation to psychiatry. For more information, readers can access the full article titled "The Structures, Functions, and Roles of Class III HDACs (Sirtuins) in Neuropsychiatric Diseases" in the journal Cells. [Extracted from the article]

A recent study from West Bengal, India, explores rare clinical presentations of Paediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS) in children and adolescents. The study highlights unique symptoms such as dissociative disorder and hoarding disorder following streptococcal infections, shedding light on the importance of awareness in diagnosing such cases. The research, conducted by authors from the Department of Psychiatry, emphasizes the need for further understanding and recognition of these manifestations in the Indian subcontinent. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the use of deep brain stimulation (DBS) targeting the nucleus accumbens (NAc) as a potential treatment for neuropsychiatric disorders such as depression, anxiety, and addiction. The study utilized high-resolution spatial transcriptomics to analyze gene expression changes in the mouse brain following NAc DBS. The findings revealed widespread alterations in synaptic function and neuronal connectivity, particularly in glutamate receptor-expressing neurons in the NAc. The study sheds light on the molecular mechanisms underlying NAc DBS and its potential therapeutic effects on neuropsychiatric disorders. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the importance of timing in behaviors and the disruptions in temporal processing and timed performance that are reported in neuropsychiatric disorders such as Schizophrenia, Autism Spectrum Disorder (ASD), Fragile X Syndrome (FXS), and Attention-deficit Hyperactivity Disorder (ADHD). The abstract describes a novel Temporal Pattern Discrimination Task (TPSD) for awake-behaving mice, which was used to study learning impairments in Fmr1-/- mice, a mouse model of FXS. The study found that Fmr1-/- mice showed significant impairment in learning the TPSD task, but displayed equivalent performance on visual-only stimuli compared to the multimodal task. This research provides insights into timing difficulties and multisensory integration issues in FXS and offers a potential assay to examine the associated neural dysfunction. [Extracted from the article]

The University of Southern California has been issued a patent for a method of decoding neuropsychiatric states, such as mood or anxiety, from large-scale brain network activity. The method involves receiving brain activity signals from an electrode assembly, decoding the mood or neuropsychiatric state of the subject from the signals, and providing a signal indicating the detected state. The patent also describes an apparatus for implementing this method and a method for adaptive tracking of brain network activity. This invention could potentially lead to the development of tailored therapies for conditions like depression and anxiety. The patent discusses various techniques for extracting neural signal features and selecting predictive networks, and the method can be used with both single-site and multisite electrode arrays. [Extracted from the article]

A recent study conducted at the University of Connecticut discusses the potential use of liquid biopsies, specifically circulating cell-free DNA (ccfDNA), as a non-invasive diagnostic tool for neuropsychiatric disorders. The researchers highlight the challenges in diagnosing psychiatric disorders due to symptom heterogeneity and the lack of objective diagnostic tests. They provide an overview of liquid biopsies and ccfDNA technologies, as well as current research on their use as biomarkers for neuropsychiatric disorders. The study concludes by discussing future steps to unlock the potential of ccfDNA in clinical practice. [Extracted from the article]

A study conducted by researchers at the University of Belgrade explores the role of gut microbiota and its metabolites in the central nervous system. The study highlights the potential of beneficial microbes and their metabolites as adjuvant therapies for neurological and psychiatric disorders. However, the molecular mechanisms underlying this relationship are not yet fully understood. The researchers discuss the current knowledge of gut microbiota alterations in prevalent disorders such as multiple sclerosis, major depressive disorder, Alzheimer's disease, and autism spectrum disorders. They also explore cutting-edge approaches, such as culturomics and induced pluripotent stem cells (iPSCs), to further investigate host-microbe interactions and pursue personalized medicine for neuropsychiatric disorders. [Extracted from the article]

A recent report from the University of Toulouse in France explores the role of N-methyl-D-aspartate receptors (NMDARs) in neuropsychiatric disorders. The report provides a detailed description of NMDARs, including their molecular structures, activation mechanisms, and physiological roles in the brain. It also examines the involvement of NMDARs in various neuropsychiatric disorders such as stroke, epilepsy, Alzheimer's disease, schizophrenia, and depression. The report concludes by discussing the strengths and limitations of different molecular structures developed for diagnostic or therapeutic purposes. This research provides valuable insights into the understanding and potential treatment of neuropsychiatric disorders. [Extracted from the article]

A study conducted by Fudan University in Shanghai, China, has found that shift work is associated with a higher risk of neuropsychiatric disorders, including dementia, anxiety, depression, and sleep disorders. The study analyzed data from 254,646 participants and found that shift work was correlated with a decrease in the volume of certain brain regions. The researchers also identified common pathways linking shift work to these disorders, such as increased immune response and glucose levels. The study highlights the need for personalized management and monitoring of shift worker health. [Extracted from the article]

This article discusses a clinical trial, NCT06602622, that is studying the effects of changing HIV treatment on body weight. The trial will include patients who have developed metabolic syndrome after starting HIV treatment or antiretroviral therapy and have gained at least 10% of their body weight. Participants will be randomly assigned to either continue their current treatment or switch to another treatment. The study will evaluate changes in body weight, BMI, lipid profile, body composition, cardiovascular risk, kidney function, and neuropsychiatric disorders over a period of 48 weeks. The document outlines the procedures and methods for the trial, including medical interviews, informed consent, and various measurements and tests. The goal is to determine the impact of switching HIV medication regimens on weight and BMI. The trial is currently recruiting participants and is expected to be completed by November 2025. [Extracted from the article]

Researchers from Henan Agricultural University in Zhengzhou, China have developed a heterogeneous neural network (H-Net) to classify multiple classes of neuropsychiatric disorders (NDs) using structural and functional magnetic resonance imaging (sMRI and fMRI). The H-Net model includes an MLP-based encoder, a GAT-based encoder, and a cross-modality transformer block to extract information from each mode and improve classification accuracy. The researchers validated the H-Net model on a public dataset and achieved 90% accuracy in diagnosing multi-class NDs. The study also demonstrated the complementarity of sMRI and fMRI in identifying different subclasses of NDs. [Extracted from the article]

A study conducted by researchers at the National University of Singapore examined the effects of continuous prenatal low dose rate irradiation on neurobehavior, hippocampal cellularity, messenger RNA, and microRNA expression in B6C3F1 mice. The study found that prenatal chronic irradiation with a low dose rate of 100 mGy/d and an accumulative dose of 1.8 Gy or below did not induce significant adverse health effects on the offspring. The researchers suggest that further study of different low dose rate radiation exposures with accumulative high doses may provide threshold doses for setting radiation safety guidelines. [Extracted from the article]

A report from Huazhong University of Science and Technology in Wuhan, China discusses the use of psychoactive substances such as hallucinogens, MDMA, and ketamine for the treatment of severe mental health disorders. The report highlights the mechanisms of action and positive clinical outcomes observed in controlled environments. Hallucinogens like LSD and psilocybin have shown promise in treating depression and anxiety disorders, while MDMA has been effective in alleviating symptoms of post-traumatic stress disorder. Ketamine has also demonstrated rapid alleviation of depressive symptoms. However, caution is necessary in the clinical application of these substances to prevent abuse and manage potential adverse effects. [Extracted from the article]

A recent preprint study explores the causal relationships between cortical morphology (surface area and thickness of the brain's cortex) and neuropsychiatric disorders. Using Mendelian randomization and sensitivity analyses, the researchers investigate the links between 70 measures of cortical morphology and 199 neuropsychiatric, behavioral, and metabolic phenotypes. The study finds that total brain cortical surface area has significant positive causal effects on 18 phenotypes, including cognitive performance, while global mean cortical thickness reduces the risk of schizophrenia. The findings suggest potential avenues for intervention studies to improve brain health. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study investigated the performance of mice in the rodent Continuous Performance Test (rCPT) to assess attentional function, which is often impaired in neuropsychiatric disorders. The study found that extending the duration of the rCPT session from 45 to 90 minutes resulted in a decline in performance in male mice, similar to what is observed in clinical research. However, physical engagement with the task remained stable, indicating that the decline in performance was due to a time-on-task-dependent vigilance decrement rather than physical disengagement. The study also explored the effects of amphetamine, an FDA-approved treatment for ADHD, on rCPT performance and found that it improved performance by reducing false alarms. These findings validate the use of the rCPT as a tool for studying human neuropsychiatric disorders. [Extracted from the article]

A recent peer-reviewed Viewpoint review published in Genomic Psychiatry explores the potential role of the trace amine-associated receptor 1 (TAAR1) gene in understanding and treating neuropsychiatric disorders. The review highlights the connection between rare TAAR1 mutations and various psychiatric conditions, such as schizophrenia and bipolar disorder. The authors suggest that understanding how TAAR1 variants affect brain function could lead to more personalized treatment approaches and potentially even genetic testing for TAAR1 mutations in psychiatric care. However, larger studies are needed to fully understand the significance of these genetic variants, and further research is required to explore how TAAR1 mutations might affect drug efficacy and side effects. This analysis represents a significant step towards unraveling the genetic architecture of mental health conditions and may open new doors for diagnosis, treatment, and prevention. [Extracted from the article]

Researchers from Sichuan University in China have conducted a study on systemic lupus erythematosus (SLE), a complex autoimmune disease. The study aimed to identify specific autoantigens associated with different subtypes of SLE. Through transcriptomic analysis and epitope mapping, the researchers identified vasodilator-stimulated phosphoprotein (VASP) as a potential autoantigen. They found that the anti-VASP antibody was significantly elevated in SLE patients with neuropsychiatric involvement, particularly those with demyelination symptoms. The researchers suggest that anti-VASP antibodies could serve as promising biomarkers for neuropsychiatric disorders in SLE. [Extracted from the article]

Sumitomo Pharma Co. Ltd. has been issued a patent for a bicyclic pyridine derivative. The compound has agonist activity on the trace amine-associated receptor TAAR1 and may be useful as a therapeutic agent for neuropsychiatric disorders such as depression, schizophrenia, and Parkinson's disease. The patent describes the compound's chemical structure and provides claims for its use in pharmaceutical compositions and methods of treating neurological or psychiatric disorders. This information may be of interest to researchers studying ADHD, antipsychotics, pharmaceutical companies, and related topics in health and medicine. [Extracted from the article]

Researchers at the University of Copenhagen have conducted an 18-year follow-up study on the Copenhagen Prospective Study on Asthma in Childhood (COPSAC2000) birth cohort. The study aims to identify risk factors for atopic diseases, obesity, and neuropsychiatric disorders through extensive characterization of the environment, clinical phenotyping, and biosampling. The study collected biomaterials and information on environmental exposures, risk behaviors, and metabolic characterizations from 370 participants. The dataset provides a unique opportunity to explore risk factors and underlying mechanisms of these prevalent non-communicable diseases. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital in Zhejiang, China, explored the potential causal relationship between neuropsychiatric disorders and non-alcoholic fatty liver disease (NAFLD). The researchers used Mendelian randomization analysis to assess the association between NAFLD and various mental disorders. The results showed that NAFLD significantly increased the risk of anxiety disorders, while major depressive disorder was identified as a potential risk factor for NAFLD. The study emphasizes the importance of recognizing and understanding the connection between neuropsychiatric disorders and NAFLD to prevent the development of related diseases. [Extracted from the article]

A recent study collected data from a large group of marmoset monkeys to understand their natural behavior patterns. The researchers found that these behavioral measurements varied significantly from day to day and were influenced by the behavior of their cage mates and the vocalization rate of other animals in the colony. The study also demonstrated that outlier detection can be used to identify atypical responses to different stimuli. This research provides valuable insights for using marmosets as models for neuropsychiatric disorders. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent report from Sapienza University of Rome discusses pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). These disorders are characterized by acute-onset obsessive-compulsive disorders, eating restrictions, tics, cognitive and behavioral deterioration, and sleep abnormalities. The research suggests that these conditions are likely caused by inflammatory mechanisms involving the basal ganglia, with autoantibodies and neuronal autoantigens playing a role. This review aims to describe the immunological features of these disorders and their potential role in their pathogenesis and clinical manifestations. [Extracted from the article]